Production (Stage)
Coya Therapeutics, Inc.
COYA
$5.61
-$0.0151-0.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 257.90K | 2.00K | -- | 3.43M | 126.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 257.90K | 2.00K | -- | 3.43M | 126.80K |
| Cost of Revenue | 5.21M | 1.94M | 2.22M | 4.57M | 3.14M |
| Gross Profit | -4.96M | -1.94M | -2.22M | -1.14M | -3.01M |
| SG&A Expenses | 2.71M | 2.14M | 2.22M | 2.09M | 2.44M |
| Depreciation & Amortization | 6.80K | 6.80K | 6.80K | 6.80K | 6.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.93M | 4.08M | 4.45M | 6.66M | 5.58M |
| Operating Income | -7.68M | -4.08M | -4.45M | -3.24M | -5.46M |
| Income Before Tax | -7.31M | -3.64M | -4.02M | -2.89M | -5.05M |
| Income Tax Expenses | -- | -720.30K | -- | -- | -- |
| Earnings from Continuing Operations | -7.31M | -2.92M | -4.02M | -2.89M | -5.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.31M | -2.92M | -4.02M | -2.89M | -5.05M |
| EBIT | -7.68M | -4.08M | -4.45M | -3.24M | -5.46M |
| EBITDA | -7.67M | -4.07M | -4.44M | -3.23M | -5.45M |
| EPS Basic | -0.44 | -0.18 | -0.26 | -0.19 | -0.35 |
| Normalized Basic EPS | -0.27 | -0.14 | -0.17 | -0.12 | -0.22 |
| EPS Diluted | -0.44 | -0.18 | -0.26 | -0.19 | -0.35 |
| Normalized Diluted EPS | -0.27 | -0.14 | -0.17 | -0.12 | -0.22 |
| Average Basic Shares Outstanding | 16.72M | 16.36M | 15.22M | 14.92M | 14.46M |
| Average Diluted Shares Outstanding | 16.72M | 16.36M | 15.22M | 14.92M | 14.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |